Cempra (CEMP): Preview Of Upcoming Catalyst - Jefferies

October 24, 2016 7:39 AM EDT
Get Alerts CEMP Hot Sheet
Price: $3.00 -6.25%

Rating Summary:
    2 Buy, 12 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade CEMP Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Jefferies analyst, Eun Yang, reiterated his Buy rating on shares of Cempra, Inc. (NASDAQ: CEMP) ahead of the FDA panel for lead product Solithera (Soli) for CABP on 11/4/16, negative sentiment stemming from liver safety concerns heavily weighs on shares. Given the prior document discussions & other approved antibiotics profiles, the analyst believes these concerns are overblown. Significant downside (>50%) exists if the panel vote is negative but the analyst views a more likely positive outcome (~70-80% likelihood), risk/reward skews to the upside (>50%).

No change to the price target of $45.

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $23.76 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment